Last Updated: September 24, 2026

Details for New Drug Application (NDA): 074014


✉ Email this page to a colleague

« Back to Dashboard


NDA 074014 describes KETOPROFEN, which is a drug marketed by Actavis Labs Fl Inc, Alkermes Gainesville, Mylan, Misemer, Rising, Teva, and Perrigo, and is included in ten NDAs. It is available from five suppliers. Additional details are available on the KETOPROFEN profile page.

The generic ingredient in KETOPROFEN is ketoprofen. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the ketoprofen profile page.
Summary for 074014
Tradename:KETOPROFEN
Applicant:Misemer
Ingredient:ketoprofen
Patents:0
Pharmacology for NDA: 074014
Mechanism of ActionCyclooxygenase Inhibitors
Medical Subject Heading (MeSH) Categories for 074014
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Suppliers and Packaging for NDA: 074014
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KETOPROFEN ketoprofen CAPSULE;ORAL 074014 ANDA Misemer Pharmaceuticals, Inc. 0276-0504 0276-0504-10 100 CAPSULE in 1 BOTTLE (0276-0504-10)
KETOPROFEN ketoprofen CAPSULE;ORAL 074014 ANDA Misemer Pharmaceuticals, Inc. 0276-0506 0276-0506-10 100 CAPSULE in 1 BOTTLE (0276-0506-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength25MG
Approval Date:Jan 29, 1993TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:Jan 29, 1993TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength75MG
Approval Date:Jan 29, 1993TE:RLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links